Infusion of neoTCR-engineered T cells into patients
We performed repeated peripheral blood sampling from patients to study the engraftment and expansion of the neoTCR transgenic T cells after infusion over time. The peak of total neoTCR transgenic T cells detected in blood samples from patients increased with the increase in cell dose. The increase occurred at a median time of 2 days after infusion (range of 1–15 days) for the 16 patients who received treatment. Moreover, the per cent of neoTCROne role of the lymphodepleting conditioning regimen is to increase the availability of the T cell homeostatic expansion cytokines IL-7 and IL-15 in serum, which favours the expansion of the infused T cellsneoTCR transgenic T cells recovered from blood after infusion generally maintained the phenotypes of the infusion product, and T memory stem cells and T effector-like cells were the predominant phenotypes (Extended Data Fig. 